Instil Bio, Inc. (TIL)
NASDAQ: TIL · Real-Time Price · USD
5.55
+0.12 (2.21%)
At close: Nov 19, 2026, 4:00 PM EST
5.55
0.00 (0.00%)
After-hours: Nov 19, 2026, 4:10 PM EST
Instil Bio Employees
Instil Bio had 17 employees as of December 31, 2025. The number of employees increased by 3 or 21.43% compared to the previous year. That makes Instil Bio the 38,935th largest employer in the world and 5,639th in the United States.
Employees
17
Change (1Y)
3
Growth (1Y)
21.43%
Revenue / Employee
n/a
Profits / Employee
-$1,229,412
Market Cap
37.64M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 14 | -35 | -71.43% |
| Dec 31, 2023 | 49 | -143 | -74.48% |
| Dec 31, 2022 | 192 | -220 | -53.40% |
| Jun 30, 2022 | 463 | 156 | 50.81% |
| Mar 31, 2022 | 437 | 195 | 80.58% |
| Dec 31, 2021 | 412 | 262 | 174.67% |
| Sep 30, 2021 | 382 | 232 | 154.67% |
| Jun 30, 2021 | 307 | - | - |
| Mar 31, 2021 | 242 | - | - |
| Dec 31, 2020 | 150 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Caribou Biosciences | 97 |
| Alps Group | 93 |
| Biomea Fusion | 37 |
| Cue Biopharma | 29 |
| Actinium Pharmaceuticals | 27 |
| Veru Inc. | 20 |
| Serina Therapeutics | 16 |
| Apollomics | 14 |
TIL News
- 3 days ago - Instil Bio Reports Third Quarter 2026 Financial Results and Provides Corporate Update - GlobeNewsWire
- 3 months ago - Instil Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update - GlobeNewsWire
- 6 months ago - Instil Bio Reports First Quarter 2026 Financial Results and Provides Corporate Update - GlobeNewsWire
- 7 months ago - Instil Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 10 months ago - Instil Bio downgraded to Neutral from Buy at H.C. Wainwright - TheFly
- 10 months ago - Baird downgrades Instil Bio on discontinuation of AXN-2510 - TheFly
- 10 months ago - Instil Bio downgraded to Neutral from Outperform at Baird - TheFly
- 10 months ago - Instil Bio’s Axion discontinues clinical development of AXN-2510 - TheFly